Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR7466] to Fatty Acid Synthase
  • Suitable for: WB, IHC-P, Flow Cyt, ICC/IF
  • Knockout validated
  • Reacts with: Human

Overview

  • Product name

    Anti-Fatty Acid Synthase antibody [EPR7466]
    See all Fatty Acid Synthase primary antibodies

  • Description

    Rabbit monoclonal [EPR7466] to Fatty Acid Synthase

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    Flow Cyt
    Human
    ICC/IF
    Human
    IHC-P
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human Fatty Acid Synthase aa 2450-2550 (C terminal). The exact sequence is proprietary.

  • Positive control

    • HeLa, 293T and A549 cell lysates; Human liver tissue; A549 cells

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Images

  • Western blot - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Western blot - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)

    Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: Fatty Acid Synthase knockout HAP1 cell lysate (20 µg)
    Lane 3: A549 cell lysate (20 µg)
    Lane 4: Hu liver tissue lysate (20 µg)
    Lanes 1 - 4: Merged signal (red and green). Green - ab128870 observed at 250 kDa. Red - loading control, ab18058, observed at 124 kDa.

    ab128870 was shown to react with Fatty Acid Synthase in wild-type HAP1 cells along with additional cross reactive bands. No band was observed when Fatty Acid Synthase knockout samples were examined. Wild-type and Fatty Acid Synthase knockout samples were subjected to SDS-PAGE. ab128870 and ab18058 (loading control to Vinculin) were both diluted at 1/10,000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

  • Flow Cytometry - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Flow Cytometry - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Overlay histogram showing A549 cells stained with ab128870 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab128870, 1/1000 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. This antibody gave a positive signal in A549 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
  • Western blot - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Western blot - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    All lanes : Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870) at 1/10000 dilution

    Lane 1 : HeLa cell lysate
    Lane 2 : 293T cell lysate
    Lane 3 : A549 cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat-anti-rabbit HRP at 1/2000 dilution

    Developed using the ECL technique.

    Predicted band size: 273 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)

    ab128870, at a 1/100 dilution, staining Fatty Acid Synthase in paraffin embedded Human liver tissue by Immunohistochemistry.

    Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

  • Immunocytochemistry/ Immunofluorescence - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Immunocytochemistry/ Immunofluorescence - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    ab128870, at a 1/250 dilution, staining Fatty Acid Synthase in A549 cells by Immunofluorescence.
  • OI-RD Scanning - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    OI-RD Scanning - Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Equilibrium disassociation constant (KD)
    Learn more about KD

    Click here to learn more about KD
  • Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)
    Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-Fatty Acid Synthase antibody [EPR7466] (ab128870)

© 2021 Astana Biomed Group LLP. All rights reserved.